Meeker County Memorial Hospital

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Colorectal cancer2 trials
• Multiple myeloma2 trials
• Childhood cancers1 trial
• Chronic myeloid leukaemia1 trial
• Lung cancer1 trial
• Neuroendocrine tumours1 trial
• Ovarian cancer1 trial

Phase

• Phase 36 trials
• Phase 21 trial

Status

• Active, not recruiting4 trials
• Completed3 trials

Lead sponsor

• National Cancer Institute (NCI)6 trials
• ETOP IBCSG Partners Foundation1 trial

Running trials

• Active, not recruiting

  Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma

  NCT00644228· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

  NCT00602641· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

  NCT00569127· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia

  NCT00070499· Phase 2· National Cancer Institute (NCI)· Source

Closed trials

• Completed

  Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery

  NCT00324805· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer

  NCT00217737· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

  NCT00066690· Phase 3· ETOP IBCSG Partners Foundation· Source